Efficacy of Adjuvant Immunochemotherapy With OK-432 for Patients With Curatively Resected Gastric Cancer: A Meta-Analysis of Centrally Randomized Controlled Clinical Trials

Journal of Immunotherapy

Volumn 25, Issue 5, 2002, Pages 405-412

  Sakamoto, Junichi ^a   Teramukai, Satoshi ^a   Nakazato, Hiroaki ^a   Sato, Yuji ^a   Uchino, Junichi ^b   Taguchi, Tetsuo ^b   Ryoma, Yoshiki ^b   Ohashi, Yasuo ^b  

^a KYOTO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Adjuvant immunochemotherapy; Gastric cancer; Meta analysis; OK 432

Indexed keywords

ANTINEOPLASTIC AGENT; CARMOFUR; DOXIFLURIDINE; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C; PICIBANIL; TEGAFUR;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MANTEL HAENSZEL TEST; META ANALYSIS; PRIORITY JOURNAL; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; ODDS RATIO; PICIBANIL; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 0036733213     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200209000-00004     Document Type: Article

References (27)

1. Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. Semin Oncol 1996; 23:281-91.
2. Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Cancer Tokyo: Kanehara & Co., Ltd.;1995.
3. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995; 333:32-41.
4. Wingo P, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer L Clin 1995; 45:8-30.
5. Franceschi S, Levi F, La Vecchia C. Epidemiology of gastric cancer in Europe. Eur J Cancer Prev 1994; 3:5-10.
6. Douglass HO, Stablein DM. Controlled trial of adjuvant chemotherapy after curative resection for gastric cancer. Cancer 1982; 49:1116-22.
7. Alcobendas F, Mula A, Estape J, et al. Mytomycin-C as an adjuvant in resected gastric cancer. J Ann Surg 1983; 198:12-7.
8. Grau JJ, Estape J, Alcobendas F, et al. Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomized trial on 134 patients. Eur J Cancer 1993; 29A:340-2.
9. Chou FF, Sheen-Chen SM, Liu PP, et al. Adjuvant chemotherapy for respectable gastric cancer: a preliminary report. J Surg Oncol 1994; 57:239-42.
10. Neri B, de Leonardis V, Romano S, et al. Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicenter randomized Br J Cancer 1996; 73:549-53.
11. Cirera LI, Balil A, Batiste-Alentorn E, et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999; 17:3810-5.
12. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized study. J Clin Oncol 1993; 11:1441-7.
13. Hermans J, Bonenkamp H. Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal: in replay. J Clin Oncol 1994; 12:879-80.
14. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35:1059-64.
15. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000; 11:837-43.
16. Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322:352-8.
17. Okamoto H, Shoin S, Koshimura S, et al. Studies of the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 1967; 11:323-36.
18. Breslow NE, Day NE. Statistical methods in cancer research. Vol.1 The analysis of case-control studies. Lyon: International Agency for Research on Cancer Scientific Publication, 1980.
19. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719-48.
20. Fujimoto T, Duda RB, Szilvasi A, et al. Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J Immunol 1997; 158:5619-26.
21. Tsuchiya I, Kasahara T, Yamashita K, et al. Induction of inflammatory cytokines in the pleural effusion of cancer patients after the administration of an immunomodulator, OK-432: role of IL-8 for neutrophil infiltration. Cytokine 1993; 5:595-603.
22. Okamoto M, Kaji R, Kasetani H, et al. Purification and characterization of Interferon-γ-inducing molecule of OK-432, a penicillin-killed Streptococcal preparation, by monoclonal antibody neutralizing Interferon-γ-inducing activity of OK-432. J Immunother 1993; 13:232-42.
23. Uchida A, Micksche M. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432. J Natl Cancer Inst 1983; 71:673-80.
24. Wei Y-Q, Zhao X, Kariya Y, et al. Induction of autologous tumor killing by heat treatment of fresh human tumor cells: involvement of γT cells and heat shock protein 70. Cancer Res 1996; 56:1104-10.
25. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989; 7:1447-56.
26. Kondo T, Sakamoto J, Nakazato H. Alternating immunochemotherapy of advanced gastric carcinoma: a randomized comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection. Biotherapy 1991; 3:287-95.
27. Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 1994; 343:1122-6.